Ontology highlight
ABSTRACT:
SUBMITTER: Merino D
PROVIDER: S-EPMC3382939 | biostudies-literature | 2012 Jun
REPOSITORIES: biostudies-literature
Mérino Delphine D Khaw Seong L SL Glaser Stefan P SP Anderson Daniel J DJ Belmont Lisa D LD Wong Chihunt C Yue Peng P Robati Mikara M Phipson Belinda B Fairlie Walter D WD Lee Erinna F EF Campbell Kirsteen J KJ Vandenberg Cassandra J CJ Cory Suzanne S Roberts Andrew W AW Ludlam Mary J C MJ Huang David C S DC Bouillet Philippe P
Blood 20120426 24
The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-x(L), and Bcl-w in vitro, we find that Bcl-2 is the critical target in vivo, suggesting that patients with tumors overexpressing Bcl-2 will probably benefit. In human non-Hodgkin lymphomas, high expression of Bcl-2 but not Bcl-x(L) predicted sensitivity to ABT-263. Moreove ...[more]